eli lily retatrutide Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Eli Lilly touts new weight-loss

Studies have demonstrated its ability to reduce plasma levels of pro-inflammatory cytokines such as IL-6 and TNF- [124]

We believe that a better understanding of the reasons could help address the barriers to continued use of these medications. Their cross-sectional study examined electronic health record (EHR) data of 288 patients with overweight or obesity and without type 2 diabetes who initiated injectable semaglutide or tirzepatide and discontinued treatment within the first year, 145 of whom received semaglutide, and 143 tirzepatide

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial

Around half of this would still have been fine

They offer their drugs directly to patients for around $500 a month